Skip NavigationSkip to Content
Return Return to Search Results

SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)

  1. Author:
    Sábato, Sofía
    Benet, Susana
    Rogers, Angela J
    Murray, Thomas A
    Skeans, Melissa
    Mothe, Beatriz
    Paredes, Roger
    Mourad, Ahmad
    Kiweewa, Francis
    Kamel, Dena
    Jain, Mamta K
    Lutaakome, Joseph
    Nalubega, Mary Grace
    Sebudde, Nicholus
    Mylonakis, Eleftherios
    Braun, Dominique L
    Hatlen, Timothy
    Kimuli, Ivan
    Kitko, Cissy
    Mugerwa, Henry
    Kitonsa, Jonathan
    Kim, Kami
    Tien, Phyllis C
    Highbarger, Jeroen
    McCormack,Ashley
    Sanchez, Adriana
    Murray, Daniel D
    Babiker, Abdel G
    Davey, Victoria J
    Files, D Clark
    Gelijns, Annetine C
    Higgs, Elizabeth S
    Kan, Virginia L
    Matthews, Gail V
    Pett, Sarah L
    Lane, H Clifford
    Reilly, Cavan
    Goodman, Anna L
    Lundgren, Jens D
    Moltó, José

  2. Author Address

    Fundació Contra Les Infeccions, Badalona, Spain., Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA., Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, USA., IrsiCaixa, Badalona, Spain., CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain., Department of Infectious Diseases and Immunity, University of Vic - Central University of Catalonia (UVic-UCC), Barcelona, Spain., Division of Infectious Diseases, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Strengthening Institutional Capacity for Research Administration (SICRA), Lira, Uganda., Lira Regional Referral Hospital, Lira, Uganda., UT Southwestern Medical Center, Dallas, TX, USA., MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda., Department of Medicine, Houston Methodist Hospital, Houston, TX, USA., Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland., The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA., Makerere University Lung Institute, Makerere University, Kampala, Uganda., Joint Clinical Research Centre, Lubowa, Uganda., Tampa General Hospital, University of South Florida, Tampa, FL, USA., Department of Medicine, Department of Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA, USA., NIAID, NIH, FNL (Frederick National Laboratory), Frederick, ML, USA., Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Infectious Diseases Section, VA Medical Center, Washington, DC, USA., Department of Infectious Diseases, CHIP Center of Excellence for Health, Immunity, and Infections, Rigshospitalet, Copenhagen, Denmark., MRC Clinical Trials Unit at UCL, University College London, London, UK., Office of Research and Development, US Department of Veterans Affairs, Washington, DC, USA., Division of Pulmonary, Critical Care, Allergy and Immunology, Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA., Department of Population Health Science and Policy, Icahn School of Medicine, New York, NY, USA., Division of Clinical Research, NIAID, NIH, Bethesda, USA., VA Medical Center, George Washington University, Washington, DC, USA., Kirby Institute, University of New South Wales, Sydney, Australia., National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, USA., Department of Infection at Guy 39;s and St Thomas 39; NHS Foundation Trust, King 39;s College London, London, UK., Fundaci 243; Lluita Contra Les Infeccions, Badalona, Spain. jmolto@lluita.org., Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. jmolto@lluita.org., CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. jmolto@lluita.org.,
    1. Year: 2025
    2. Date: Mar 22
    3. Epub Date: 2025 03 22
  2. Journal: Scientific Reports
    1. 15
    2. 1
    3. Pages: 9882
  4. Type of Article: Article
  5. Article Number: 9882
  1. Abstract:

    The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending on timing of vaccination and number of doses. The VATICO study randomized 66 hospitalized recovered COVID-19 individuals to receive either immediate or deferred vaccination, with one or two doses of mRNA SARS-CoV-2 vaccines. We measured binding and neutralizing antibodies against SARS-CoV-2 at enrollment and longitudinally. Median (IQR) time from SARS-CoV-2 infection to first vaccination was 68 (53-75) days in the immediate group, and 151 (137-173) days in the deferred group. At week 48, timing or number of vaccine doses did not influence the change in antibody levels relative to baseline. Adherence to the assigned vaccine regimen was lower in the deferred group, particularly in participants receiving two doses. Although the study ultimately lacked adequate power to draw firm conclusions, these results suggest possible benefits of prompt vaccination after recovery from COVID-19. © 2025. The Author(s).

    See More

External Sources

  1. View Full Text
  2. DOI: 10.1038/s41598-025-92742-x
  3. PMID: 40118946
  4. PII : 10.1038/s41598-025-92742-x

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel